(ORCL - Get Report)
($33.21) reported disappointing quarterly results after the close on Thursday, but also announced that they will raise its dividend by 100%, and will implement a $12 billion share buyback program. The company will also shift its listing to the NYSE from the Nasdaq. The stock ended Thursday just above its 200-day SMA at $33.13, but opened below my annual value level, now a pivot at $30.81. The stock has recently been downgraded to hold from buy according to ValuEngine with a quarterly value level at $27.81, an annual pivot at $30.81, a semiannual pivot at $31.89 and annual risky level at $34.68.
(TEVA - Get Report)
($38.88) received FDA approval for its Plan B One-Step for use without prescription. The stock ended Thursday just below its 50-day and 200-day SMAs at $38.92 and $39.29, and was little changed at today's open. The stock has had a buy rating according to ValuEngine for more than a year. My monthly value level is $35.89 with a weekly risky level at $40.18.
At the time of publication the author held no positions in any of the stocks mentioned.
This article is commentary by an independent contributor, separate from TheStreet's regular news coverage.